| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
*
Laboratory of Physiology, Medical School of Vrije Universiteit Brussel, Brussels, Belgium; and
Department of Molecular Biology, Université Libre de Bruxelles, Rhode-St-Genèse, Belgium
 |
Abstract |
|---|
 Top Abstract IntroductionMaterials and MethodsResultsDiscussionReferences |
|---|
|
Introduction |
|---|
|
TopAbstractIntroductionMaterials and MethodsResultsDiscussionReferences |
|---|
In an attempt to optimize the use of DCs to induce an antitumor response we have focused our efforts on the expression of the entire tumor Ag polypeptide in DCs. Genetic modification of DCs using liposome-mediated (19) or biolistic transfection strategies or adeno- and retroviral transduction (20, 21, 22, 23) has a number of potential advantages to peptide- or protein-based methods. Genetic modification does not require knowledge of the HLA haplotype of the patients or of the particular TAA peptides binding to the restriction elements. In addition, multiple and not yet defined peptide epitopes encoded by the whole tumor Ag polypeptide might contribute to T cell activation. This approach also may lead to long term presentation of the antigenic epitopes to the immune system.
We have chosen to develop this strategy by retroviral transduction of DCs with cDNA encoding a model Ag, chicken OVA. This Ag was chosen for several reasons. The E.G7-OVA cell line has been widely used for the development of immunotherapeutic strategies directed toward the surrogate TAA (i.e., OVA), and multiple reagents and tools are available (6, 10, 24, 25, 26, 27). OVA in its native form is a secreted protein, and well-defined OVA peptides are presented in the context of MHC class I and class II molecules. By deletion of part of the OVA-encoding cDNA we could limit the expression of the tumor Ag polypeptide to the cytosol, thus mimicking the expression of most TAA identified to date, and demonstrate the effect of the lack of MHC class II presentation.
We demonstrate the efficient transduction of bone marrow-derived DCs with retroviral vectors encoding GFP, the entire OVA cDNA, and a truncated OVA (tOVA) cDNA. These gene-modified DCs differentiate in vitro and express, process, and present the gene products in the context of MHC molecules. Injection of OVA cDNA-modified DCs results in potent CTL response compared with the injection of tOVA cDNA-transduced DCs. Moreover, when the transduced DCs are cultured in autologous serum and in the absence of FCS, only the DCs presenting OVA peptides in the context of both MHC class I and class II are able to induce an OVA-specific CTL response. Genetically modified DCs are potent inducers of an effective antitumor immunity against a challenge of tumor cells and against an established tumor.
|
Materials and Methods |
|---|
|
TopAbstractIntroductionMaterials and MethodsResultsDiscussionReferences |
|---|
C57BL/6 (H-2b), BALB/c (H-2d), and (C57BL/6 x BALB/c)F1 (H-2b x H-2d) female mice, 6–8 wk old, were obtained from Charles River Wiga (Sulzfeld, Germany). Animals were maintained and treated according to the institutional guidelines. The care and use of mice were in accordance with the guidelines of the Vrije Universiteit Brussel.
The tumor cell lines used were EL-4 (C57BL/6, H-2b, thymoma) and E.G7-OVA (EL-4 cells transfected with chicken albumin cDNA; American Type Culture Collection, Manassas, VA). Cells were maintained in DMEM (Life Technologies, Ghent, Belgium) supplemented with 5% heat-inactivated FCS, 2 mM glutamine, 50 µM 2-ME, 100 U/ml penicillin, and 100 µg/ml streptomycin. E.G7-OVA cells were grown in the same medium containing 400 µg/ml G418 (Calbiochem, Bierges, Belgium). When used as targets in CTL assays, these cells were grown in the same medium containing 1% autologous serum during the last 48–72 h before the assay. The T cell hybridoma RF33.70 recognizes an H-2-Kb OVA peptide (amino acids 257–264) and was provided by Dr. K. L. Rock (Boston, MA). The H-2-I-Ad-restricted OVA-specific T cell hybridoma DO11.10 recognizes an I-Ad-binding epitope located within amino acids 323–339 of the OVA protein sequence. This cell line was provided by Dr. P. Marrack. Upon recognition of the OVA epitopes in the context of the corresponding restriction element, these T cell hybridomas secrete IL-2. The amount of IL-2 released in the supernatant of the DC-T cell hybridoma cocultures was determined using the indicator cell line CTLL-2. All cell lines were free of mycoplasma as tested by PCR analysis (Mycoplasma PCR primer set, Stratagene, Westburg, Leusden, The Netherlands).
The rmGM-CSF was produced in-house as previously described (28). The rmIL-4 was 11B11 mAb affinity purified from supernatant of sF9 cells infected with a recombinant baculovirus provided by Dr. J. Van Snick (UCL, Brussels, Belgium). The biological activity of rmIL-4 was determined using IL-4-dependent TS1 cells. As a source of rhFLT3-L we used a 200-fold dilution of a supernatant of CHO cells transfected with pCDNA3-FL (containing 2 µg of rhFLT3-L/ml). This vector was generated by PCR using HS86 DNA as template. The HS86 plasmid was given to us by O. Rosnet (Laboratoire d’Oncologie Moléculaire, Marseille, France). The biological activity of rhFLT3-L was determined with OCI-AML-5 cells. All cytokines produced by ourselves were endotoxin-free (<15 pg/ml) as analyzed by a colorimetric assay (Chromogenic, Molndal, Sweden).
Generation of bone marrow-derived DCs and cell phenotype
The procedure used to generate DCs from bone marrow cultures was that described by Mayordomo et al. (6) with minor modifications. Briefly, bone marrow was flushed from the long bones of the limbs, filtered through a nylon mesh, and depleted of red cells with ammonium chloride. Bone marrow cells were incubated for 30 min with a panel of mAbs for the depletion of lymphocytes, granulocytes, and MHC class II-positive cells. All the Abs used were purchased from PharMingen (San Diego, CA). Ab-labeled cells were incubated with sheep anti-rat Ab-coated magnetic beads (Dynal, Oslo, Norway) at a cell-to-bead ratio of 1:5. Lineage marker-negative cells were plated in 24-well culture plates (106 cells/ml; 1 ml/well) in DMEM supplemented with 5% heat-inactivated FCS or 1% heat-inactivated autologous serum, 50 µM 2-ME, 2 mM glutamine, 100 U/ml penicillin, 100 µg/ml streptomycin, and 10 ng/ml rhFLT3-L. After overnight incubation the cells were replated (2.5 x 105 cells/well in 1 ml) in the same medium containing cytokines (rmGM-CSF, 200 ng/ml; rmIL-4, 1000 U/ml; rhFLT3-L, 10 ng/ml). From day 6 on the DC were cultured in the absence of serum. The nonadherent cells were harvested on day 6, extensively washed with Opti-MEM (Life Technologies), and further cultured in the same medium in the presence of rmGM-CSF and rmIL-4. On days 8–10 DC were harvested by gentle pipetting.
For phenotypic analysis, DCs were incubated with the biotinylated mAbs
directed against the surface molecules B7-1, B7-2, CD11c, MHC classes I
and II, or appropriate isotype-matched controls in the presence of
2.4G2 supernatant, a rat Ab directed against the mouse FcRII
(CD32)
receptor. Binding of the mAbs was revealed by a second incubation with
PE-labeled streptavidin (PharMingen).
Cloning of retroviral vector constructs
For retrovirus production the retroviral vector MFG, derived from Moloney murine leukemia virus, was used. This vector does not contain a drug resistance marker, nor does it express any potential antigenic protein other than the inserted cDNA (29). All the cDNAs were obtained by PCR. The amplification products were sequenced before insertion into the MFG vector. For amplification of OVA cDNA we used the pAc-neo-OVA plasmid (provided by Dr. Bevan, La Jolla, CA) as template. Two OVA-MFG vectors were generated: MFG-OVA containing the whole OVA cDNA (amino acids 1–386) and MFG-tOVA containing the cDNA encoding a truncated form of the OVA protein sequence (amino acids 40–386). The cDNA encoding the reporter gene GFP was amplified from plasmid pRS-GFP-C1 (Clonetech, Westburg, Leusden, The Netherlands).
Ten million PhoenixECO producer cells (provided by Dr. G. P. Nolan, Stanford, CA) were transfected with 40 µg of retroviral vector DNA by the calcium phosphate precipitation method (following the instructions given by Dr. Nolan) (30). Cells were incubated in chloroquine (Sigma, St. Louis, MO) containing medium at 37°C for 10 h. The medium was again changed (Opti-MEM) after 14 h, and the retrovirus-containing medium was harvested 48 h after transfection. The retroviral supernatants were filtered (0.45 µm pore size), snap-frozen, and stored at -80°C.
Transduction of DCs
On days 2, 3, and 4 after the start of the bone marrow cell culture, the medium was removed and replaced with 1 ml of virus supernatant containing 8 µg/ml polybrene (Sigma). The cells were transduced during centrifugation of the 24-well plates during 2 h at 2500 rpm and at 32°C. The retroviral supernatant was then removed, and the cells were resuspended in cytokine-containing medium. This transduction procedure was repeated two more times.
Mixed lymphocyte reaction
The ability of transduced and nontransduced DCs to stimulate resting T cells was assessed by a mixed lymphocyte reaction. Mitomycin C-treated C57BL/6 bone marrow-derived DCs harvested on day 8 or 10 or mitomycin C-treated splenocytes were plated at graded concentrations in the presence of 3 x 105 BALB/c nylon wool-purified T cells in 200 µl of DMEM with supplements. After 3-day incubation at 37°C, 5% CO2 the cells were pulsed overnight with 1.0 µCi/well [3H]thymidine. [3H]thymidine incorporation was measured using a beta scintillation counter (Microbeta, Wallac, Turku, Finland).
Ag presentation assay
To determine whether the transduced DCs presented OVA-derived peptides in the context of MHC class I and class II molecules, OVA-specific T cell hybridoma cells (5 x 104 cells/well in a final volume of 200 µl) were cocultured with graded numbers of transduced DCs harvested on days 6–8 in round-bottomed 96-well tissue culture plates and incubated at 37°C in a 5% CO2 humidified incubator. After 20–22 h, the supernatant was harvested, and IL-2 release was measured by the proliferation assay with CTLL-2 cells.
Induction of Ag-specific CTLs in vivo and cytotoxicity assay
Naive mice were immunized with transduced DCs (105 cells in 200 µl of PBS) by a single i.v. injection. To demonstrate the dependence on CD4+ T lymphocytes during the induction phase, CD4+ T cells were depleted before immunization, by i.p. injection of 1 mg of anti-CD4 Ab GK1.5 (5 days before the immunization) followed by injections of 250 µg 7 and 14 days later.
Fourteen days after the injection of the DCs, the splenocytes from the immunized mice were depleted of APCs by plastic adherence and were restimulated in vitro with mitomycin C-treated E.G7-OVA cells at a responder to stimulator ratio of 10:1 for 5 days in culture medium supplemented with 1% autologous mouse serum and 10 U of IL-2/ml. On day 6 restimulated splenocytes were tested for Ag-specific cytolytic activity using E.G7-OVA and EL-4 cells as targets. These cells were labeled with 200 µCi of Na251CrO4 (Amersham, Arlington Heights, IL). Restimulated splenocytes were mixed in graded doses with 104 labeled target cells in 200 µl of tissue culture medium in V-bottom 96-well tissue culture plates (Costar, Cambridge, MA). Cells were incubated for 4 h at 37°C in a 5% CO2 humidified incubator. The release of 51Cr was measured with a gamma counter (Kontron, Van Hopplynus, Brussels, Belgium), and the percent specific lysis was calculated as follows: 100 x [(experimental release - spontaneous release)]/[(maximal release - spontaneous release)]. Spontaneous and maximal release were determined in the presence of either medium or 10% SDS. Spontaneous release was <10%. The SD of triplicate wells was <10%.
Protection against tumor challenge by transduced DCs
C57BL/6 mice were immunized by i.v. injection with 2 x 105 transduced DCs on days 0 and 7. One week after the last immunization (day 14), 107 E.G7-OVA or EL-4 cells were injected s.c. in the interscapular region. Mice were monitored on a regular basis for tumor growth and tumor volume (smallest diameter2 x largest diameter) (31). This method of tumor volume assessment correlated very well with the tumor weight determined after resection of tumors. Statistical significance was calculated using the one-sided t test. Mice with a tumor diameter >3 cm were killed.
Suppression of tumor growth by transduced DCs
Groups of five to eight C57BL/6 mice were inoculated with 5 x 106 E.G7-OVA cells on day 0. These mice were treated with four i.v. injections of 2 x 105 transduced DCs (days 4, 8, 12, and 16). Mice were monitored as described above. The Ag expression by the tumors escaping the immunotherapy was analyzed by RT-PCR. RNA was extracted from the resected tumor tissue by TRIzol extraction (Life Technologies). First-strand cDNA was synthesized using a preamplification cDNA synthesis kit (Life Technologies). RT-PCR was performed with the following primers: sense primer, 5'-gggggatccaggggaaacacatctgccaa; and antisense primer, 5'-gggggatccatttgccagtgggacaat. An RT-PCR using actin-specific primers was used to assess the quantity and the quality of the cDNA.
|
Results |
|---|
|
TopAbstractIntroductionMaterials and MethodsResultsDiscussionReferences |
|---|
Lineage marker-negative bone marrow cells were cultured in the
presence of several cytokines and growth factors to enhance the
expression of retroviral receptors and cellular division. After a 24-h
culture period in the presence of rhFLT3-L, the cells were transduced
during a 120-min centrifugation step at 32°C in the presence of
supernatant of the ecotropic packaging cell line PhoenixECO and 8
µg/ml polybrene. The transduction was repeated three times. This
method of gene transduction has been used for the successful
transduction of human DCs (20), has been reported to enhance the
transduction efficiency compared with other methods (32), and avoids
the potential contamination of the differentiating cells with packaging
cells. The transduced cells were allowed to differentiate into DCs
during another 7–8 days in the presence of rmGM-CSF and rmIL-4.
Transduction efficiency and the phenotype of the DCs were monitored
cytofluorographically. Using GFP as reporter system, we consistently
obtained a cell population of which the majority of the cells displayed
a green fluorescence (mean, 74; range, 52–86%; in 27 independent
experiments). A representative FACS analysis of mock-, GFP-, OVA-, or
tOVA-transduced cells, cultured in 1% NMS, and stained with DC surface
markers (CD80, CD86, MHC class II, and CD11c) is shown in Fig. 1
. The cells displayed the characteristic
DC morphology, with large extensions (not shown). DC cultured in 5%
FCS displayed the same characteristics (not shown). It is important to
mention here that there was no difference in the expression of surface
markers or viability between the DCs transduced with the different
constructs.
|
The effect of retroviral transduction of the DCs on their
stimulatory capacity was assessed in an allogeneic MLR (Fig. 2). Both the mock-transduced as well as
the GFP- or OVA-transduced DC populations induced a strong
proliferation of allogeneic T cells. No significant differences were
noted among the different retroviral constructs used or the culture
conditions during the expansion and the differentiation of DCs. The
stimulatory capacity of the DCs was consistently at least 1000-fold
stronger than the stimulatory effect of bulk splenocytes.
|
The capacity of the retrovirally transduced DCs to process and
present OVA-derived peptides in the context of MHC complexes was
determined by their coculture with the OVA-specific T-T hybridoma cell
lines DO11.10 (OVA323–339-Ad specific) and
RF33.70 (OVA257–264-Kb specific). After a 22-h
coculture of graded numbers of transduced CB6F1 (BALB/c x
C57BL/6) DCs with the Ag-specific cell lines, the IL-2 released in the
supernatant was measured. DCs transduced with the entire OVA cDNA
presented OVA peptides in the context of both MHC class I and class II
(Fig. 3). DCs expressing the truncated
OVA cDNA (amino acids 40–386) presented OVA peptides only in an MHC
class I-restricted fashion. OVA peptide-pulsed DCs were used as
positive controls (not shown). Mock-transduced or GFP-transduced DCs
did not activate the OVA-specific cell lines, demonstrating the
specificity of the T-T hybridoma response. These results indicate that
the endogenously expressed cDNAs were processed and presented on the
surface of the DCs. However, the cytosolic expressed tOVA retaining the
OVA323–339 sequence but lacking a signal sequence for
translocation into the ER was not presented in association with MHC
class II molecules, while the OVA257–264 presentation in
the context of H2-Kb was indistinguishable between the two
DC populations transduced with either OVA or tOVA cDNA.
|
To determine whether the transduced DCs could induce an
OVA-specific CTL response in vivo, C57BL/6 mice were immunized with a
single i.v. injection of 105 transduced DCs. Splenocytes
from immunized mice were harvested 2 wk later, restimulated in vitro
with E.G7-OVA cells, and then assayed for specific lysis of target
cells in a standard 51Cr release assay. When the DCs had
been cultured in the presence of FCS until the day of immunization,
OVA-transduced as well as tOVA-transduced DCs induced an Ag-specific
CTL response. The CTL response in tOVA-transduced DC-immunized mice was
consistently weaker than that in the mice immunized with OVA-transduced
DCs, a finding repeatedly observed in several independent experiments.
Immunization with GFP-transduced DCs failed to generate specific
cytolytic CTLs. Negligible lysis of non-OVA-expressing EL4 target cells
was detected when the in vivo primed pCTLs were restimulated in vitro
in the presence of autologous normal mouse serum (data not shown). When
the transduced DCs were cultured in the absence of FCS for 72 h
before immunization, the difference in CTL response after OVA- and
tOVA-transduced DC immunization became even more pronounced. Fig. 4 shows the data from five independent
experiments. Similar results were obtained when F1 DCs pulsed in vitro
with class I-restricted peptides alone or with class I plus class II
peptides were used for immunization (data not shown). When the DCs had
been cultured in the presence of autologous serum from day 1 on, no
OVA-specific CTLs could be induced by the tOVA-transduced DCs, while
the OVA-transduced DCs were still potent inducers of a strong CTL
response (Fig. 4).
|
). The lack of
any response in these mice indicated that CD4+ T cells are
essential for CTL priming in vivo. Induction of protective immunity against E.G7-OVA tumor cells by immunization with transduced DCs
To determine whether transduced DCs would induce protective
immunity against a tumor cell challenge, mice were immunized i.v. with
2 x 105 irradiated OVA- or GFP-transduced or
nontransduced DCs on days 14 and 7 before tumor challenge (on day 0).
The mice were challenged with 10 million tumor cells and were monitored
for tumor growth. Compared with untreated mice, the tumor growth was
slightly retarded in mice immunized with GFP-transduced DCs (data not
shown). In mice immunized with OVA-transduced DCs, tumor growth was
significantly slowed (Fig. 5A).
|
The therapeutic efficacy of retrovirally transduced DCs was also
assessed (Fig. 5B). Five million tumor cells were injected
on day 0, and these mice (groups of five to eight mice) were treated
with four injections of 2 x 105 irradiated OVA- or
GFP-transduced DCs (days 4, 8, 12, and 16). Mice treated with DCs
transduced with OVA showed a significant (p <
0.05) retardation of tumor growth compared with mice treated with
GFP-transduced DCs, indicating the Ag specificity of the antitumor
immunity. The results shown are representative of data obtained from
two independent experiments. At the highest tumor load the effect of
the irradiation of the DCs was most apparent, while in the mice with a
smaller tumor burden no difference between irradiated and nonirradiated
DCs was noted (data not shown). However, after 3 wk tumors started to
grow progressively in the mice immunized with OVA-transduced DCs.
Analysis of the resected tumor tissues indicated that Ag-negative
variants had been selected, since none of the biopsies taken from
OVA-transduced DC-treated mice generated an OVA-specific PCR
amplification product, while tumors resected from mice treated with
GFP-transduced DC all showed a strong PCR signal (data not shown). This
further indicates that the transduced DCs induced a strong immune
response eradicating all Ag-expressing tumor cells.
|
Discussion |
|---|
|
TopAbstractIntroductionMaterials and MethodsResultsDiscussionReferences |
|---|
In this report we have presented a strategy allowing optimal presentation of TAA by DCs independent of the limitations described above. We have chosen to develop this strategy by retroviral transduction of DCs with a model Ag gene encoding chicken OVA. Several groups have reported the successful transduction of human and murine DCs in vitro by retrovirus vectors encoding a model Ag (ß-galactosidase) and tumor Ags including the melanoma MART-A Ag and the human epithelial tumor Ag mucin (20, 23, 33, 34). We show that bone marrow progenitor cell-derived DCs can be efficiently retrovirally transduced with MFG-OVA encoding OVA in its native form or MFG-tOVA, a truncated form of OVA lacking a signal sequence for translocation in the ER. The data provide evidence that the transduced DCs are able to process and present endogenously expressed OVA. The native form of OVA is presented in the context of both MHC class I and MHC class II molecules, as evidenced by recognition and specific IL-2 release by OVA-specific T cells. The truncated form of OVA, tOVA, is presented in the context of MHC class I only. Efficient presentation of Ag in class II requires endocytosis of the protein and processing in the early endosomes, where peptides can be loaded in the class II dimers. The complete OVA protein contains a targeting sequence that allows translocation into the ER and the secretory pathway of the Golgi apparatus. After secretion, the protein can be endocytosed by the cells and enter the exogenous class II presentation pathway. The fact that there is indeed a secretion of the OVA protein when DCs were transduced with the native protein is proven by the detection of OVA protein in the supernatant of cultured transduced DCs by Western blot (data not shown). The truncated form of OVA however lacks the ER translocation sequence and is present in the cells as a cytoplasmic protein. The truncated OVA will therefore enter the proteasome degradation pathway, thus generating peptides that will be loaded onto the MHC class I proteins. The fact that indeed OVA was no longer secreted after deletion of the signal sequence was proven by the fact that we were unable to detect OVA protein in the supernatant of tOVA-transduced DCs.
We show that retroviral transduction of DCs does not influence their capacity to be potent stimulators in an allo-MLR compared with non- or mock-transduced DCs, nor did it influence the expression of DC-specific markers. We enhanced the expression of retroviral receptors and cellular division of lineage-bone marrow-derived progenitor cells by incubating the cells with FLT3-L, granulocyte-macrophage CSF, and IL-4. Kotani et al. (32) have reported that centrifugation of retroviral vector supernatant onto the target cells increased the gene transfer efficiency 4- to 18-fold in NIH-3T3 fibroblasts and 3-fold in HUT78 cells. This in combination with the enhanced proliferation of the cells by using FLT3-L resulted in a transduction efficiency of a mean of 74%, ranging from 52–86%, as shown with the reporter gene GFP when DCs were cultured in 5% FCS. Transduction of DCs cultured in NMS resulted in lower transduction efficiencies, ranging from 40–75%. This approach offers an advantage to the method described by Specht et al. (23), where bone marrow cells are transduced in coculture with the producer line, thus avoiding any potential contamination with the packaging cells.
The two versions of the same Ag, whole OVA and a truncated form of OVA, allowed us to study the requirement of CD4+ T cell help for the in vivo priming of CTLs. The CTL response elicited by MFG-tOVA-transduced DCs was enhanced when the DCs were cultured in the presence of FCS, indicating that significant Th cell responses are generated in vivo because of the exposure of DCs to FCS during the in vitro expansion and differentiation. This finding has major implications for the design of human trials using DCs, in which the use of FCS should be avoided. The nonspecific help derived from FCS components was only partially reduced by culturing the DCs for 72 h before injection in serum-free medium. When the DCs had never been exposed to FCS but instead were generated in the presence of autologous mouse serum, no CTLs were primed in vivo. In contrast, presentation of the antigenic peptides in the context of both MHC class I and class II by the MFG-OVA-transduced DCs cultured in the absence of FCS resulted in a strong CTL response. This response was absent in CD4+ T cell-depleted B6 mice. This indicates that a washout period of 72 h is not sufficient to empty all the preformed MHC class II-peptide complexes and that the OVA-specific CTL response is CD4+ T cell dependent. These data are in agreement with the findings that the (serum) proteins endocytosed by the immature DCs may persist for a long time and are presented when the cells mature. These mature DCs have long-lived MHC class II/peptide complexes on their surface (35, 36). We want to underline the importance of our methodology, i.e., using DCs generated and transduced in the absence of any foreign Ag, in particular fetal bovine protein. Indeed, a prerequisite for translating the promising results obtained in experimental animal models to human studies is the ability to induce T cell responses with DCs that have not been exposed to bovine Ag.
These results confirm the idea that in vivo priming of CTLs requires the interaction of APCs, CD4+, and CD8+ T cells. There are many examples of CD4+ T cell-dependent CTL responses (16, 17). Animal models of tumor and viral immunity have shown that the generation and persistence of a CTL response are dependent upon the presence of a CD4+ Th cell response. Recently, Bennett et al. (14) clearly demonstrated that the induction of a CTL response by cross-priming requires cognate CD4+ T cell help. Moreover, their experiments indicated that the CD4+ and CD8+ T cells need to recognize Ag on the same APC. They further suggested that the APC-CD4+ T cell interaction in some way alters the APC function so that they become superactivated and stimulatory for CD8+ T cells. This interaction, as first suggested by Grueder and Matzinger (15), involves the CD40-CD40 ligand molecules expressed on DCs and T cells (37, 38, 39). In line with this study, Ossendorp et al. (18) showed that specific Th cells are required for optimal induction of CTL against MHC class II-negative tumors.
A single immunization of no more than 105 genetically modified DCs resulted in high and transgene-specific tumor cell lysis. We successfully used these transduced DCs in the vaccination of naive animals that were protected against a subsequent tumor challenge after receiving two i.v. injections of no more than 2 x 105 DCs. We also significantly suppressed the tumor growth in tumor-bearing animals by treating them with DCs transduced with the native form of OVA. Radiation of the DCs had no influence when we used a tumor dose of <107 E.G7 OVA cell/mouse. Radiation of DCs was performed in the context of using this approach in the treatment of human malignancies. However, it is known that radiation of cells renders them apoptotic, thus reducing the time of Ag presentation in vivo. This was clearly only important when we injected the mice with high tumor doses (107 E.G7 OVA cell/mouse). However, when we transduced the DCs with the native OVA and tested the presence of OVA peptide in the context of MHC class I or class II molecules, we observed no difference between irradiated and nonirradiated DCs (data not shown). Thus, it is clearly not a matter of a reduction in presentation as a consequence of the irradiation but, rather, of a decrease in DC viability and duration of presentation in vivo.
Cells that eventually grew out of the tumor were tumor Ag-negative variants, as shown by an OVA-specific RT-PCR. This finding could be interpreted as either an indication of the effectiveness of the immunotherapy or as an important mechanism of tumor escape. Further studies are needed to analyze the underlying escape mechanism.
Our current and future efforts are focused on the presentation of the tumor-derived antigenic peptides in the context of both MHC class I and class II by specifically targeting the Ag to the endosomal/lysosomal pathway and/or to enhance the cytosolic degradation. The efficient presentation of tumor Ags in the context of both MHC class I and class II molecules should lead to more powerful immune responses. Strong CD4+ Th cell function is desirable to induce tumor-specific CD8+ effector T cells and long term immune memory.
|
Acknowledgments |
|---|
|
Footnotes |
|---|
2 Address correspondence and reprint requests to Dr. Kris Thielemans, Laboratory of Physiology, Medical School of Vrije Universiteit Brussel, Laarbeeklaan 103, B-1090 Brussels, Belgium. E-mail address:
3 Abbreviations used in this paper: DC, dendritic cell; TAA, tumor-associated Ag; GFP, green fluorescent protein; tOVA, truncated OVA; rmGM-CSF, recombinant murine granulocyte-macrophage CSF; rmIL, murine rIL; rhFLT3-L, recombinant human FLT3 ligand; PE, phycoerythrin; NMS, normal mouse serum.
Received for publication May 4, 1998. Accepted for publication September 8, 1998.
|
References |
|---|
|
TopAbstractIntroductionMaterials and MethodsResultsDiscussionReferences |
|---|
This article has been cited by other articles:
|
|
 |
|
  M. A. Barber, T. Zhang, B. A. Gagne, and C. L. Sentman NK Cells Negatively Regulate Antigen Presentation and Tumor-Specific CTLs in a Syngeneic Lymphoma Model J. Immunol., May 15, 2007; 178(10): 6140 - 6147. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S.-C. Yang, R. K. Batra, S. Hillinger, K. L. Reckamp, R. M. Strieter, S. M. Dubinett, and S. Sharma Intrapulmonary Administration of CCL21 Gene-Modified Dendritic Cells Reduces Tumor Burden in Spontaneous Murine Bronchoalveolar Cell Carcinoma. Cancer Res., March 15, 2006; 66(6): 3205 - 3213. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. P. J. J. Hegmans, A. Hemmes, J. G. Aerts, H. C. Hoogsteden, and B. N. Lambrecht Immunotherapy of Murine Malignant Mesothelioma Using Tumor Lysate-pulsed Dendritic Cells Am. J. Respir. Crit. Care Med., May 15, 2005; 171(10): 1168 - 1177. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. S. K. Yee, Y. Yao, Q. Xu, B. McCarthy, D. Sun-Lin, M. Tone, H. Waldmann, and C.-H. Chang Enhanced Production of IL-10 by Dendritic Cells Deficient in CIITA J. Immunol., February 1, 2005; 174(3): 1222 - 1229. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. Kuipers, C. Heirman, D. Hijdra, F. Muskens, M. Willart, S. van Meirvenne, K. Thielemans, H. C. Hoogsteden, and B. N. Lambrecht Dendritic cells retrovirally overexpressing IL-12 induce strong Th1 responses to inhaled antigen in the lung but fail to revert established Th2 sensitization J. Leukoc. Biol., November 1, 2004; 76(5): 1028 - 1038. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. Okada, T. Tsugawa, H. Sato, N. Kuwashima, A. Gambotto, K. Okada, J. E. Dusak, W. K. Fellows-Mayle, G. D. Papworth, S. C. Watkins, et al. Delivery of Interferon-{alpha} Transfected Dendritic Cells into Central Nervous System Tumors Enhances the Antitumor Efficacy of Peripheral Peptide-Based Vaccines Cancer Res., August 15, 2004; 64(16): 5830 - 5838. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. Stober, I. Jomantaite, R. Schirmbeck, and J. Reimann NKT Cells Provide Help for Dendritic Cell-Dependent Priming of MHC Class I-Restricted CD8+ T Cells In Vivo J. Immunol., March 1, 2003; 170(5): 2540 - 2548. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B. Chmielowski, R. Pacholczyk, P. Kraj, P. Kisielow, and L. Ignatowicz Presentation of antagonist peptides to naive CD4+ T cells abrogates spatial reorganization of class II MHC peptide complexes on the surface of dendritic cells PNAS, November 12, 2002; 99(23): 15012 - 15017. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Y. Ikuta, N. Katayama, L. Wang, T. Okugawa, Y. Takahashi, M. Schmitt, X. Gu, M. Watanabe, K. Akiyoshi, H. Nakamura, et al. Presentation of a major histocompatibility complex class 1-binding peptide by monocyte-derived dendritic cells incorporating hydrophobized polysaccharide-truncated HER2 protein complex: implications for a polyvalent immuno-cell therapy Blood, May 15, 2002; 99(10): 3717 - 3724. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A C Armstrong and R E Hawkins Vaccines in oncology: background and clinical potential Br. J. Radiol., November 1, 2001; 74(887): 991 - 1002. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Ponnazhagan, G. Mahendra, D. T. Curiel, and D. R. Shaw Adeno-Associated Virus Type 2-Mediated Transduction of Human Monocyte-Derived Dendritic Cells: Implications for Ex Vivo Immunotherapy J. Virol., October 1, 2001; 75(19): 9493 - 9501. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Ponnazhagan, D. T. Curiel, D. R. Shaw, R. D. Alvarez, and G. P. Siegal Adeno-associated Virus for Cancer Gene Therapy Cancer Res., September 1, 2001; 61(17): 6313 - 6321. [Full Text] [PDF]
|
|
|
|
|
|
C. Meyer zum Buschenfelde, J. Metzger, C. Hermann, N. Nicklisch, C. Peschel, and H. Bernhard The Generation of Both T Killer and Th Cell Clones Specific for the Tumor-Associated Antigen HER2 Using Retrovirally Transduced Dendritic Cells J. Immunol., August 1, 2001; 167(3): 1712 - 1719. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Toungouz, M. Libin, F. Bulte, L. Faid, F. Lehmann, D. Duriau, M. Laporte, D. Gangji, C. Bruyns, M. Lambermont, et al. Transient expansion of peptide-specific lymphocytes producing IFN-{gamma} after vaccination with dendritic cells pulsed with MAGE peptides in patients with mage-A1/A3-positive tumors J. Leukoc. Biol., June 1, 2001; 69(6): 937 - 943. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. W. Ju, Q. Tao, G. Lou, M. Bai, L. He, Y. Yang, and X. Cao Interleukin 18 Transfection Enhances Antitumor Immunity Induced by Dendritic Cell-Tumor Cell Conjugates Cancer Res., May 1, 2001; 61(9): 3735 - 3740. [Abstract] [Full Text]
|
|
|
|
|
|
S. Liu, Y. Yu, M. Zhang, W. Wang, and X. Cao The Involvement of TNF-{{alpha}}-Related Apoptosis-Inducing Ligand in the Enhanced Cytotoxicity of IFN-{{beta}}-Stimulated Human Dendritic Cells to Tumor Cells J. Immunol., May 1, 2001; 166(9): 5407 - 5415. [Abstract] [Full Text] [PDF]
|
|
|
